Objective-Vascular endothelial dysfunction is a key component of several major human diseases, but the molecular basis of this complex disorder has been difficult to determine in vivo. Previous attempts to identify key mediators of vascular endothelial dysfunction in experimental models have been limited by the lack of suitable methods for system-wide analyses of vascular bed biology. Here, we aimed to develop a novel method for investigating vascular endothelial dysfunction pathogenesis that enables system-wide analyses of molecular interactions between endothelial glycocalyx, endothelial cells, and smooth muscle cells in murine. Approach and Results-We developed a new technique using whole-body differential perfusion with increasing concentrations of detergent buffer to selectively solubilize distinct layers of vascular bed tissue in rodents. When combined with proteomics techniques, our novel approach of differential systemic decellularization in vivo enabled quantitative profiling of vascular beds throughout the body. Initial perfusion with phosphate buffer was used to obtain the endothelial glycocalyx, followed by subsequent extraction of endothelial cell components, and finally by smooth muscle cell constituents with increasing concentrations of detergent. Differential systemic decellularization in vivo has also been successfully applied to characterize molecular events in the vascular bed pathology of lipopolysaccharide-challenged mice. Conclusions-Together, these data indicate that differential systemic decellularization in vivo permits system-wide molecular characterization of vascular bed proteomes in rodent models and can be used to advance our current understanding of vascular endothelial dysfunction pathogenesis and progression in a wide range of disease settings. Visual Overview-An online visual overview is available for this article.
V ascular endothelial dysfunction (VED) is a common feature of several major human diseases, including cancer, atherosclerosis, stroke, and dementia. 1, 2 Each of these diseases is increasing in prevalence as the global population ages, thus early identification and characterization of VED has become a leading health research priority around the world. VED impairs the vasodilatory ability of endothelial cells (ECs) and smooth muscle cells (SMCs) to confer these populations with proinflammatory and prothrombotic properties that promote the development of vascular pathology. [3] [4] [5] Although several different host factors have already been implicated in this systemic disorder, the key molecular mechanisms that drive VED pathogenesis remain largely unknown. 6 ECs cover the luminal portion of the vasculature and feature an irregularly shaped apical layer of carbohydrate-rich mucosa known as the endothelial glycocalyx (eGC), which may dysregulate platelet aggregation, capillary leakage, and vascular tone when subject to shear stress. [7] [8] [9] [10] Pathological modifications to the eGC have been poorly defined at the molecular level, although previous studies have reported that eGC thickness is negatively correlated with inflammation in atherosclerosis, 11 suggesting that eGC tissue composition is significantly altered in disease. Similarly, VED is thought to arise from disruption of the complex signaling patterns that prevent mesenchymal transition of ECs, 8 leading to abnormal secretion of extracellular matrix proteins that promote vascular inflammation and atherosclerosis, 12, 13 but the critical mediators of these pathological processes in vivo are not well understood.
Although VED is a systemic disorder, current methods are unable to support the simultaneous molecular characterization of multiple vascular beds throughout the body in experimental models. 14 We, therefore, developed a novel method of differential systemic decellularization in vivo (DISDIVO), which
Animals
Ten-week-old male C57BL/6NT mice were housed in cages on a 12-hour dark/light cycle at controlled temperature (21°C) and fed standard commercial chow with water provided ad libitum (please see the Major Resources Table in the online-only Data Supplement for more information). All animals were allowed to adapt to these conditions for a minimum of 2 weeks before being experimentally used. For method optimization, animals were divided into 7 groups with n=3 (control, DISDIVO-PBS, and 5 DISDIVO-sodium deoxycholate [SDC] treatments [0.5%, 1%, 2%, 5%, and 10% SDC]). All experimental procedures were approved by the Nanyang Technological University Institutional Animal Care and Use Committee and were performed humanely and in strict accordance with the International Guiding Principles for Animal Research. 15 Although sex should be carefully considered as a biological variable in clinical studies, the nature of this study was to optimize and validate a novel method to systemically study in vivo endothelial dysfunction in animal models of human pathology. Therefore, to minimize interindividual variability and investigate the technical variability intrinsically derived from DISDIVO, we have only and consistently used wild-type male mice in this study.
Enrichment of EC and SMC by DISDIVO
Mice were initially anesthetized by intraperitoneal injection with ketamine-xylazine (90-10 mg/kg) and then administered isoflurane by inhalation for the duration of the experimental procedures (IsoFlo; VeterinariaEsteve, Bologna, Italy). The animals were subjected to DISDIVO as summarized in Figure 1 . First, the wall of the right auricle was cut with scissors to allow exsanguination by transcardial whole-body perfusion, while at the same time 30-gauge needle was inserted into the left ventricle to permit introduction of 1× PBS at a flow rate of 1.5 mL/min. After ≈1.5 minutes, removal of circulating blood was complete (no visible traces remaining in the right auricle exudate) and collection of the PBS fraction was initiated for 3 to 4 minutes before sample storage at −80°C until further analysis. Whole-body decellularization of vascular beds was then performed by introducing 100 mmol/L ammonium acetate buffer containing SDC at a concentration ranging from 0.5% to 10% in 50 mmol/L TrisHCl buffer perfused throughout the circulatory system at a rate of ≈1.5 mL/min. The outflow buffer containing decellularized vascular bed tissue was then carefully collected from the open right auricle (total sample volume ≈4 mL) and stored at −80°C until analysis. The DISDIVO experiments were performed per triplicate. DISDIVO was also tested gradually in duplicate for whole-body decellularization of vascular beds by perfusing every animal with 50 mmol/L Tris-HCl buffer containing 0.5% SDC for 3 to 4 minutes, and subsequently, the SDC concentration during the perfusion was increased to 10%. Both outflows in this gradual condition were collected separately.
Lipopolysaccharide Challenge of Mice
A total of 6 mice were injected with lipopolysaccharide derived from Escherichia coli O55:B5 freshly prepared in sterile PBS as previously described. 16 Lipopolysaccharide was administered intraperitoneally in a single injection at 20 mg/kg of body weight. Lipopolysaccharidechallenged animals were equally distributed in 3 groups (DISDIVO-PBS, DISDIVO-0.5%, and DISDIVO-10%) and kept for 6 hours before being anesthetized and subjected to DISDIVO procedures.
In-Solution Digestion of DISDIVO Fractions
Tryptic digestion was performed as previously described except for minor modifications. 17 Briefly, DISDIVO-SDC fractions (1% SDC was added to DISDIVO-PBS fractions) were diluted to <1% SDC with 50 mmol/L ammonium acetate, and vascular bed proteomes were reduced using 10 mmol/L dithiothreitol for 30 minutes at 60°C. The proteomes were subsequently alkylated with 20 mmol/L iodoacetamide for 45 minutes at room temperature in the dark. Samples were then diluted 2-fold with 100 mmol/L ammonium acetate containing 10 mmol/L dithiothreitol and incubated for 30 minutes at 37°C. Tryptic digestion was performed overnight at 30°C using sequencing-grade-modified trypsin at 1:50 (w/w) enzymeto-protein ratio. Enzymatic digestion was quenched by addition of a final concentration of 0.5% formic acid (FA) to each sample. Peptide recovery was then performed as follows: SDC was pelleted by centrifugation of the acidified sample at 12 000g for 10 minutes. The supernatant was then collected into a new tube, and the remaining SDC pellet was redissolved in 0.5% ammonium hydroxide before reprecipitation with 0.5% FA. SDC precipitation and peptide recovery were performed twice, and the supernatants combined. Supernatant samples containing the digested tryptic peptides were desalted using a C-18 Sep-pack 1g cartridge (Waters, Milford, MA). Eluates were finally dried in the vacuum concentrator (Eppendorf, Hamburg, Germany).
Homogenization and Tryptic Digestion of Aorta Tissues
Thoracic aorta tissues were excised from DISDIVO-PBS mice and littermate controls and dissected to remove outer fat layers. Aorta tissues (≈3 mg) were then accurately weighted using a Metler Toledo AX26 Delta Range analytical balance (Metler Toledo, Gießen, Germany). Homogenization of aorta tissues was performed as previously described with minor modifications. 18 Briefly, tissue homogenization was performed in 200 µL of 16 mol/L urea prepared in 100 mmol/L ammonium bicarbonate supplemented with Complete Protease Inhibitor cocktail using a bullet blender homogenizer (Next Advance, NY). Beads (≈3 mg of 0.5 mm zirconium oxide breads) and safe-lock tubes were used throughout all the homogenization process. Homogenization of aorta tissues in the bullet blender homogenizer was performed at maximum intensity (speed 10) in repeated cycles of 5 minutes till no remaining pellet was observable. The safe-lock tubes were centrifuged at 15 000g for 10 minutes, and the supernatant was collected at the end of each homogenization cycle. All homogenization procedures were performed at 4°C, and all the obtained homogenization supernatants were combined. In-solution tryptic digestion of aorta homogenates was performed as previously described with minor modifications. 19 Briefly, homogenates initially prepared in 16 mol/L urea prepared in 100 mmol/L ammonium bicarbonate were 2-fold diluted with water before reduction. Proteins were then reduced with 10 mmol/L dithiothreitol for 3 hours at 30°C and subsequently alkylated with 20 mmol/L iodoacetamide during 45 minutes at room temperature in dark conditions. Samples were subsequently diluted to <1 mol/L urea with 50 mmol/L ammonium bicarbonate and digested overnight with sequencing-grademodified trypsin at 1:25 (w/w) enzyme-to-protein ratio. Tryptic digestion was quenched by addition of 0.5% FA. Digested samples were desalted using a C-18 Sep-pack 200 mg cartridge (Waters). Eluates were finally dried in the vacuum concentrator (Eppendorf, Hamburg, Germany). Proteomics data obtained from each aorta tissues were adjusted on the basis of the measured aorta weight, and the experiments were performed in duplicate.
High-Pressure Liquid Chromatography Fractionation
Desalted peptides were fractionated by high-pressure liquid chromatography as previously described. 20 Briefly, the dried peptides were reconstituted in 200 µL mobile phase A (10 mmol/L ammonium hydroxide in water) and fractionated using a XBridge BEH130 C18 3.5 μm 4.6 ×250 mm column (Waters, Elstree, UK) on a Shimadzu Prominence UFLC system (Dionex, Sunnyvale, CA) with UV monitoring of peptide intensities at 280 nm performed throughout. Peptide separation was performed at 1 mL/min using a 72-minute gradient as follows: 0% mobile phase B (10 mmol/L ammonium hydroxide in acetonitrile) for 5 minutes, 0% to 20% for 30 minutes, 20% to 33% for 15 minutes, 33% to 60% for 10 minutes, and 60% to 100% for 5 minutes, followed by 7 minutes at 0% mobile phase B. Fractions were collected at 1-minute intervals and combined by concatenation. Concatenated fractions were then completely dried in the vacuum concentrator.
Liquid Chromatography Tandem-Mass Spectrometry
Dried sample fractions were carefully reconstituted in mobile phase A (3% acetonitrile, 0.1% FA) before peptide analysis by LC-MS/ MS using a Dionex UltiMate 3000 UHPLC system coupled with an Orbitrap Elite mass spectrometer (Thermo Fisher, Inc, Bremen, Germany). 18, 19 Spray was generated using a Michrom Thermo 
RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction
Tissues for real-time quantitative polymerase chain reaction (qPCR) were accurately weighted using a Metler Toledo AX26 Delta Range analytical balance. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) with on-column DNaseI digestion. Reverse transcription was performed using iScript Reverse Transcription Supermix (Bio-Rad Laboratories, Inc, Hercules, CA) according to the manufacturer's instructions to generate cDNA. Quantitative real-time PCR was performed using the CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories) with the KAPA SYBR FAST qPCR Master Mix (KAPA Biosystem, Wilmington, MA). GAPDH was used as internal control. Data were adjusted in every sample based on total RNA/mg tissue. The primer sequences used for qPCR experiments are provided in Table I in the online-only Data Supplement.
Tissue Preparation for Confocal Microscopy
Thoracic aorta tissues were excised from DISDIVO mice and littermate controls then carefully dissected, and the outer fat layers removed. Whole brains were removed from the skulls and the cortices dissected, and livers were excised, and the left lobe dissected before tissue preparation for immunohistochemistry as previously reported. 21 Briefly, the dissected tissues were washed 3 times in 1× PBS for 5 minutes at 4°C before fixation in 4% paraformaldehyde (in 1× PBS) for 48 hours at 4°C. Tissue samples were then cryoprotected by immersion in 30% sucrose containing 0.02% sodium azide for 1 week before storage at −20°C. Sectioning of the tissues was performed using a CM1950 cryostat (Leica, Wetzlar, Germany) to obtain 16-µm-thick sections that were placed on adhesive SuperFrost Ultra Plus microscope slides (Thermo Scientific) and stored at −80°C.
Immunocytochemistry and Image Analysis
Permeabilization of tissue sections was performed using 0.1% Triton X-100 in 1× PBS for 1 hour. Sections were subsequently blocked with 10% heat-treated horse serum in 1× PBS for 1 hour at room temperature. Permeabilized and blocked sections were then incubated overnight at 4°C with one of the following primary antibodies: rabbit polyclonal anti-PECAM1 (10 µg/mL, ab28364), goat polyclonal anti-ACTA2 (4 µg/mL, ab21027), from Abcam (Cambridge, UK) or rat monoclonal anti-PECAM1 (10 µg/mL, NB100-1642) from Novus Biologicals (Littleton, CO; please see the Major Resources Table in the online-only Data Supplement). After staining, the tissue sections were repeatedly washed with 1× PBS for a 40-minute period and then incubated for 1 hour at room temperature with appropriate AlexaFluor-conjugated secondary antibodies (2 µg/mL) from Jackson ImmunoResearch (West Grove, PA) or Abcam (4 µg/mL; Cambridge, UK; please see the Major Resources Table in the online-only Data Supplement). The AlexaFluor antirat conjugated secondary antibody from Abcam was kindly provided by Radoslaw Omelianczyk from Dr Preiser's laboratory at Nanyang Technological University. Slides were prepared using antifade mounting media (Vectashield or Fluoroshield). Aorta, brain, and liver slides from 3 different animals were processed and imaged in parallel using a Fluoview FV-1000 Olympus confocal laser-scanning microscope (Tokyo, Japan). Scanning parameters were fixed for each experimental condition across treatment groups. Quantitative fluorescence microscopy measurements were performed using the Fiji image-processing package 22 for imageJ. 23 Images were processed using red, green, blue vector, and antibody intensities for each image were automatically measured within 5 polygonal areas of 100×100 pixels each placed randomly within the area of tissue immunoreactivity.
Bioinformatics and Statistical Data Analysis
Database searching of raw proteomics data was performed as previously described, 24, 25 allowing a precursor ion tolerance of 10 ppm and fragment ion tolerance of 0.05 Da in PEAKS Studio version 7.5 26 (Bioinformatics Solutions, Waterloo, Canada). False-discovery rate was set at 1% for protein identifications, and carbamidomethylation at Cys residues was set as a fixed modification. The UniProt mouse database (58 761 entries; downloaded on February 18, 2016) was used for searching. Proteins consistently identified in at least 2 animals were considered for each experimental condition tested in the DISDIVO optimization experiment. GraphPad Prism 6 (GraphPad Software, Palo Alto, CA) was used for parametric statistical analyses and creating data plots. Equality of group variances was tested by Brown-Forsythe test. Normality was assessed by D'Agostino and Pearson omnibus normality test. Statistical significance was established by ANOVA at P<0.05 followed by Bonferroni post hoc multiple comparisons, unless stated otherwise. Cluster analysis based on label-free protein quantitation (total number of spectra detected for all peptides in each protein) was performed using the fuzzy c-mean algorithm 27 in R software. Clustered lists of proteins and blood cell contamination were further analyzed using the FunRich suite. 28 Only proteins with a fuzzy partition coefficient ≥0.5 were considered in functional analyses. Data are reported as mean±SEM unless otherwise specified. Identification of plateletderived proteins was performed by bioinformatics comparison of each DISDIVO condition data with specific platelet markers data previously identified by Garcia et al. 29 The following categories of platelet proteins were considered: adaptors proteins, kinases and phosphatases, transcription and translation-associated proteins, and proteins with unknown function identified from the platelet microparticle proteome.
Availability of Data
The data generated in this study are publicly available via the ProteomeXchange consortium through the partner repository PRIDE. 30 Identifier is PXD008794.
Results

Optimization of DISDIVO for Systemic Molecular Characterization of Vascular Beds In Vivo
The decellularization ability of DISDIVO was assessed using SDC concentrations ranging from 0.5% to 10%, and the samples extracted were characterized using a systems biology approach (LC-MS/MS proteomics). Across experimental conditions, DISDIVO enabled the identification of 7742 proteins in total (the individual data sets are provided in datasets I-VI in the online-only Data Supplement). To simplify mining of these complex data, we performed fuzzy c-mean clustering 27 to facilitate data visualization, outlier estimation, and protein classification/abundance comparisons between conditions. 31 A total of 10 clusters containing an average of 283 proteins each were generated (Figure 2A through 2C ; Figure I in the online-only Data Supplement). Protein abundance as identified by LC-MS/MS displayed a clear association with SDC concentration across DISDIVO conditions (Figure 2A) , despite the increased sample variability evident at DISDIVO-5% (Figure 2A through 2C ; Figure I in the online-only Data Supplement). These findings indicated that optimal enrichment of vascular bed proteomes by DISDIVO was achieved at DISDIVO-10% (Figure 2A) , which yielded substantial sample enrichment in EC and SMC protein markers ( Figure 2E ), without the excessive viscosity generated at higher detergent concentrations.
Using the bioinformatics platform FunRich, 28 we next investigated the cellular origins of the proteins in each fuzzy c-mean cluster as identified within the DISDIVO samples (the global results obtained are shown in Figure II in the online-only Data Supplement). We observed that cluster 9 in particular was enriched in proteins of ECs origin (Figure 2A) Figure 2D ). We also observed that several SMC-specific proteins such as ACTA2 (smooth muscle actin alpha 2) were grouped within the same cluster ( Figure 2D) . Intriguingly, FunRich analysis also revealed that DISDIVO using PBS only was sufficient to significantly enrich for extracellular matrix proteins in cluster 5, which contained numerous key matrix components as further validated by comparison with the most comprehensive available database 32 ( Figure 2C ; Table I in the online-only Data Supplement).
To evaluate whether DISDIVO enables systemic decellularization of vascular beds throughout the body, we next mined the data sets obtained by preferential site of expression for specific EC markers ( Figure 4A ). This approach confirmed that DISDIVO not only enriched ubiquitous EC markers of the vascular endothelium, but also enabled identification of dermal microvascular and capillary endothelium proteins, as well as EC proteins derived from the corneal endothelium and high endothelial venules ( Figure 4A ). We also tried to investigate blood cell contamination in DISDIVO eluates, although this analysis represents a substantial challenge because many proteins attributed to blood cells are ubiquitously expressed in all populations of vascular bed cells, we found that blood cell contamination globally represents ≈17% of the total protein content in DISDIVO fractions (breakdown of this data is shown in Table II in the online-only Data Supplement).
These data indicate that DISDIVO permits proteomic analysis of systemic vascular bed composition and is, therefore, suitable for dissecting the molecular basis of systemic vascular pathologies.
DISDIVO-Based Analysis of Glycocalyx Proteins
To date, analysis of the vascular eGC in health and disease conditions has relied mainly on imaging techniques and mathematical modeling, 33 so we next explored ability of DISDIVO to enrich for proteoglycan core proteins derived from the eGC. We successfully identified multiple eGC core proteins from a total of 7 families comprising the 
Figure 4. Functional characterization of murine vascular beds proteins obtained by differential systemic decellularization in vivo (DISDIVO).
A, Analysis of endothelium-associated proteins obtained by DISDIVO-10% confirmed efficient sampling of vascular beds throughout the circulatory system. Endotheliumrelated proteins were filtered and categorized by functional enrichment analysis. B, Label-free quantification of glycocalyx core protein families. DISDIVO-PBS or DISDIVO-10% was optimal for analyses of glycocalyx composition because of consistent high total protein yields and glycocalyx core protein content. C, Characteristic glycocalyx protein profile in healthy mice as determined using DISDIVO in combination with LC-MS/MS (values shown indicate protein family abundance averaged across experimental conditions). D, Label-free quantification of glycocalyx markers present in aorta tissues before (control) and after DISDIVO-PBS treatment. Numbers in green above green columns indicate the percentage of each respective remaining marker in thoracic aorta tissues after performing DISDIVO-PBS. Perlecan quantification is indicated in the right y axis. *Statistical significance between conditions within a protein assessed by ANOVA with Bonferroni correction for multiple comparisons (P<0.05). glycocalyx 10 ( Figure 4B ). Quantitative analysis revealed that PBS flushing of the circulatory system during the first step of DISDIVO was as efficient as 10% SDC enriching for proteoglycan core proteins ( Figure 4B) , and the generated DISDIVO-PBS samples facilitated the identification of lowabundance eGC proteins, such as proteins from the versican family (which were not obscured by the high-abundance proteins subsequently recovered in the DISDIVO-SDC perfusates). Consistent with previous analyses of organ-specific eGC proteins, 34 the most abundant core protein identified by DISDIVO was the proteoglycan heparan sulfate (also known as perlecan; Figure 4C ). The detection of perlecan in DISDIVO-PBS fractions suggests a partial removal of the ECs layer during DISDIVO-PBS because of the effect of shear stress as perlecan is mainly associated with basal membrane. 35 Nevertheless, its detection also may suggest high efficiency of DISDIVO-PBS washing brain eGC, as this proteoglycan is highly expressed in the brain ECs and pericytes. 36 Other proteoglycan core protein families successfully identified by DISDIVO included syndecan, glypican, versican, decorin, biglycan, and mimecan. DISDIVO-PBS also enriched for glomerular endothelium-derived proteins such as lumican, which is likely involved in maintaining the homeostasis of the endothelial barrier 37 (supplemental dataset I in the online-only Data Supplement). Label-free quantification of eGC markers in aorta tissues before and after DISDIVO-PBS indicates successful removal of ≈50% of the total eGC proteomes present in aorta tissues by the sole effect of shear stress ( Figure 4D ; supplemental dataset VII in the online-only Data Supplement).
DISDIVO Validation by Immunostaining of Vascular Beds From the Aorta, Liver, and Brain
To validate the ability of DISDIVO to decellularize vascular beds in vivo, we next performed immunohistochemical analyses of the EC marker PECAM1 and SMC marker ACTA2 in thoracic aorta tissues from perfused mice. Consistent with our LC-MS/MS data, image analysis of PECAM1 immunostaining in mouse aorta confirmed a marked decrease in protein abundance after DISDIVO-0.5% compared with untreated controls ( Figure 5AI-IX and 5B). Immunostained PECAM1 was essentially undetectable in thoracic aorta rings processed with DISDIVO-1% to 10%, suggesting complete decellularization of the vascular endothelium proteome from 0.5% SDC. In addition, the SMC marker ACTA2 was significantly enriched only in DISDIVO buffer containing 5% to 10% SDC ( Figure 5D and 5CI-IX), confirming that high concentrations of detergent can facilitate decellularization of the SMC proteome by DISDIVO.
Having confirmed that DISDIVO permits identification of endothelium-derived proteins by mass spectrometrybased proteomics, we next evaluated the ability of this technique to extract vascular bed proteomes from peripheral organs. To do this, we performed immunohistochemistry using brain and liver tissues from DISDIVO mice and assessed immunoreactivity for ACTA2 and PECAM1 ( Figure 6 ). When performed using 0.5% SDC, DISDIVO was unable to facilitate brain proteome extraction from either the SMC ( Figure 6AI -VI and 6B) or EC ( Figure 6CI -VI and 6D). However, at SDC concentrations of 1% or higher, we detected significant depletion of ACTA2 and PECAM1 from the brain vasculature ( Figure 6A through 6D) . Similarly, detergent concentrations of ≥1% significantly decreased ACTA2 levels in the vascular beds of immunostained liver tissues ( Figure 6EI -IX and 6F), whereas PECAM1 required >2% SDC for efficient extraction by DISDIVO ( Figure 6GI -IX and 6H).
Validation of DISDIVO by Real-Time qPCR
We performed real-time qPCR to further determine the amount of ECs and SMCs markers that remain in aorta tissues after DISDIVO treatments. The markers PECAM1 (ECs) and ACTA2 (SMCs) were analyzed in these experiments (primers details provided in Table III in the onlineonly Data Supplement). No significant differences were observed in the remaining amount of PECAM1 in aorta tissues after DISDIVO-PBS ( Figure 3A) . It was only after DISDIVO-0.5% when we observed a statistically significant reduction of PECAM1 in aorta tissues as shown in Figure 3A . Of note, no significant differences were observed in amount of PECAM1 comparing DISDIVO-0.5% and DISDIVO-10% ( Figure 3A ). These data confirmed the ability of DISDIVO-0.5% to efficiently decellularize ECs. On the contrary, a significant reduction in the remaining amount of ACTA2 in aorta tissues was only achieved after performing DISDIVO-10% compared with the rest of conditions ( Figure 3B ). Together, these data were found in accordance with the previous results obtained and confirms that DISDIVO-0.5% is able to successfully lyse ECs, whereas DISDIVO-10% is required to lyse the vascular layer of SMCs.
DISDIVO Characterization of Vascular Beds From Lipopolysaccharide-Treated Mice
To test the ability of DISDIVO to identify and characterize molecular alterations in whole-body vascular beds under pathogenic conditions, we applied DISDIVO to the molecular study of vascular beds from lipopolysaccharide-challenged mice. Lipopolysaccharide is a large molecular component of Gram-negative bacteria that has been extensively reported as inducer of extensive eGC and vascular endothelium toxicity in mice. 38 Analysis of DISDIVO-PBS fractions obtained from untreated and lipopolysaccharide-challenged mice demonstrated that this drug causes a drastic shedding of eGC glycoproteins in vascular beds as shown in Figure 7 and supplemental dataset VIII in the online-only Data Supplement. Analysis of DISDIVO-0.5% and DISDIVO-10% conditions from lipopolysaccharide-challenged mice, also revealed modulation of multiple key proteins as shown in the Table. Particularly, we observed upregulation of endothelial activation markers, apoptosis markers, redox proteins, and phagocytosis induction molecules in ECs (Table) . DISDIVO was also able to identify protective responses to lipopolysaccharide as the upregulation of the apolipoprotein Apoa1 and modulation of several other proteins in ECs and SMCs, many of which were considered, to the best of our knowledge, as modulated proteins that are associated with lipopolysaccharide-induced vascular toxicity for the first time (Table) .
Discussion
The few techniques available for the study of VED pathogenesis in vivo do not account for the systemic nature of this complex syndrome, [39] [40] [41] [42] [43] which affects multiple vascular beds throughout the body. 44 Similarly, although the larger vessels can be dissected for the molecular study of their vascular layers, the molecular study of the microvasculature and capillary vascular beds represents a paramount challenge. We have, therefore, developed a novel perfusion technique termed DISDIVO, which employs progressively stronger detergent buffers to selectively decellularize vascular beds system wide in vivo. Whole-body perfusion is a versatile technique commonly used for fixation and preservation of tissues, 45 but this classical procedure can also be used to develop novel in vivo applications, including biotinylation of extracellular matrix proteins, and blood vessel visualization by lipid labeling. 43, 46 Our data indicate that the DISDIVO perfusion variant reported here provides an excellent method of sampling ECs, SMCs, and eGC molecules derived from the entire vascular system. Figure 5 . Depletion of endothelial cell (EC)-and smooth muscle cell (SMC)-associated markers from thoracic aorta after differential systemic decellularization in vivo (DISDIVO). A, Immunostaining for PECAM1 (platelet and endothelial cell adhesion molecule 1) in thoracic aorta collected from untreated control animals (I, II, and III), or those perfused with DISDIVO-PBS (IV, V, and VI), DISDIVO-0.5% (VII, VIII, and IX), or DISDIVO-1% (X, XI, and XII). White arrows indicate areas of high PECAM1 abundance located at the innermost layer of the thoracic aorta. For each condition, the image panels show DAPI (4',6-diamidino-2-phenylindole) staining (left), PECAM1 staining (center), and merged images (right). B, Relative quantification of PECAM1 in thoracic aorta shows that low concentration of sodium deoxycholate (SDC) efficiently disrupted the endothelium and significantly depleted PECAM1 from the thoracic aorta (P<0.05 compared with control) C, Image showing ACTA2 immunostaining in thoracic aorta tissues from control animals (I, II, and III) or those perfused with DISDIVO-PBS (IV, V, and VI), DISDIVO-5% (VII, VIII, and IX) or DISDIVO-10% (X, XI, and XII). For each condition, the image panels show DAPI staining (left), ACTA2 staining (center), and merged images (right). D, Relative quantification of ACTA2 in thoracic aorta demonstrated that significant recovery of SMC components by DISDIVO required SDC concentrations ≥10%. Bars=30 µm. Statistical significance was determined by ANOVA with Bonferroni correction for multiple comparisons (*P<0.05). . Image panels show either untreated control animals (I, II, and III) or those perfused with DISDIVO-0.5% (IV, V, and IV) or DISDIVO-10% (VII, VIII, and IX). For each condition, the image panels show DAPI (4',6-diamidino-2-phenylindole) staining (left), ACTA2 or PECAM1 staining (center), and merged images (right). Bar=30 µm. Quantification of ACTA2 and PECAM1 in organs collected after DISDIVO indicated that significant extraction of SMCs and ECs markers required SDC concentrations ≥ 1% for brain and ≥2% for liver. Statistical significance was determined by ANOVA with Bonferroni correction for multiple comparisons (*P<0.05).
This type of system-wide approach will be key to deciphering core mechanisms of VED pathogenesis in animal models, in particular by allowing the identification of systemic vascular changes at the earliest stages of disease rather than only localized, late-stage pathology.
Chemical decellularization is a widely used technique in regenerative medicine and tissue engineering, where a range of acids, alcohols, and detergents can be used to achieve cell removal without disrupting tissue architecture. 47, 48 The detergents most commonly used for these applications are sodium dodecyl sulfate and SDC. 47 Although sodium dodecyl sulfate displays outstanding ability to disrupt protein-protein and protein-DNA interactions, 47 we instead elected to use SDC for our decellularization strategy because of the ease with which this detergent can be precipitated out of samples by acidification. 17 The use of SDC rather than sodium dodecyl sulfate also enhances identification of peptides containing posttranslational modifications by LC-MS/MS. 17, 20, 49 During standard chemical decellularization procedures, incubation times of several hours with detergent are required to release the intracellular content of interest, 50, 51 whereas in the current study, we observed that DISDIVO-10% was able to efficiently decellularize vascular beds within just minutes. SDC concentrations exceeding 10% are, however, not recommended because of the impractical nature of the obtained solution. All together indicate that the enrichment of eGC is obtained by shear stress during DISDIVO-PBS, ECs proteome is efficiently enriched when using DISDIVO-0.5% and higher concentrations of detergent are required (DISDIVO-10%) for the efficient enrichment of SMCs. DISDIVO-0.5% and DISDIVO-10% can also be performed in a sequential manner in a single animal, as we report in Figure IV in the online-only Data Supplement, nevertheless the volume of outflow available from every sequential DISDIVO condition under this approach will be smaller because of time constraints. Additionally, DISDIVO may be applied in a single-organ perfusion 37, 52 to obtain outflows from specific organ-derived vascular beds.
Bioinformatics analyses indicated that dermal microvascular and capillary endothelium proteins were successfully enriched by DISDIVO. We not only identified EC proteins derived from corneal endothelium and high endothelial venules but also confirmed the system-wide efficiency of this technique by quantifying depletion of EC-and SMC-specific markers from liver and brain vascular beds by immunohistochemistry. These analyses also revealed that combining DISDIVO with systems biology techniques could be a promising new approach to the study of endothelial-to-mesenchymal transition pathways when using rodent diseases models, because we were able to identify and quantify basal levels of key mediators of this process (TGF-β [transforming growth factor beta 1], FGFR1 [fibroblast growth factor receptor 1]) in the DISDIVO outflows obtained from healthy animals ( Figure  V in the online-only Data Supplement). Although endothelialto-mesenchymal transition is an essential cellular mechanism in embryonic vascular development, activation of endothelialto-mesenchymal transition-linked pathways in adults can exert pathological effects on endothelial barrier function, cell fate drift, and apoptosis. 8 Therefore, when used in conjunction with appropriate rodent models of disease, DISDIVO has considerable potential to uncover new roles of endothelial-tomesenchymal transition in human disorders associated with systemic vascular pathology.
To validate the capability of DISDIVO for uncovering molecular events in vascular pathology, DISDIVO has been applied to the analysis of pathological modulation of proteins in vascular beds of lipopolysaccharide-challenged mice. Sepsis-associated mediators, such as lipopolysaccharide, are known to induce a rapid decrease of the eGC thickness and stiffness, 53, 54 fact that was observed here by a drastic vanishing of eGC components to undetectable levels in DISDIVO-PBS eluates. The proteomic analysis of DISDIVO-SDC eluates confirmed downregulation of several redox proteins, including SOD1 and SOD3, in ECs and SMCs, as well as a modulated expression of apoptotic regulatory proteins (eg, BCL-2 [B-cell lymphoma 2]).
55 PLEK (pleckstrin) was also found upregulated in ECs, indicating a possible activation of phagocytosis induced by lipopolysaccharide. 56 Similarly, ApoA1 (apolipoprotein A-I) protein was found upregulated in ECs, which suggests activation of a protective mechanism in the vasculature aimed to counteract lipopolysaccharide toxicity. 57 Lipopolysaccharide-induced VED was confirmed in this study by the identification of upregulated EC-markers in lipopolysaccharide-challenged mice including VCAM1, VWF, F2 and Sel-L, among others. DISDIVO also allowed identification of novel lipopolysaccharide-modulated proteins, which up to our knowledge have not been previously reported and include an important subset of Apo proteins in ECs (ApoA4, ApoC2, ApoC3, ApoE, and ApoH) and the protein S100A8, which is known to play important roles in inflammatory and immune processes. 58 These findings reinforce the abilities of DISDIVO to investigate the chemical composition of vascular beds in vivo in the animal models of interest, a fact of crucial importance to achieve a further comprehension of VED pathogenesis and progression in diverse concomitant syndromes and in several major human diseases.
The eGC comprises a meshwork of glycosaminoglycans, proteoglycans, glycoproteins, and associated molecules that form a distinct mucosal layer on the luminal surface of ECs. 59 This specialized tissue facilitates transvascular exchange of Upregulation and downregulation of proteins is expressed compared with the same DISDIVO condition of the nontreated group. References included in the fourth column of the table refer to the work where the protein was previously reported as modulated by LPS. Proteins are categorized according to their function. Last category of proteins corresponds to novel reported proteins identified in our study that where, up to our knowledge, not previously reported by other authors as modulated by LPS. EC indicates endothelial cell; LPS, lipopolysaccharide; SDC, sodium deoxycholate; and SMC, smooth muscle cell.
*Graphics for every cluster of proteins are included in Figure III in the online-only Data Supplement. †LPS-PBS refers to DISDIVO-PBS fraction collected from LPS-treated mice. ‡LPS-ECs refers to DISDIVO-0.5% SDC fraction collected from LPS-treated mice. §LPS-SMCs refers to DISDIVO-10% SDC fraction collected from LPS-treated mice.
solutes and water, mediates complex ligand-receptor interactions and cell adhesion, serves as a physical barrier between the blood and tissues, and converts mechanical forces into biochemical signals (mechanotransduction). 10, 60 Modification of the eGC by environmental factors, including diet, aging, and oxidative stress can, therefore, lead to significant pathology, 61 and molecular characterization of this tissue will be key to improving current understanding of vascular diseases. Other colleagues have previously used LC-MS/MS to identify eGC proteins obtained from kidney vascular beds via renal perfusion with sodium chloride, which was able to displace and elute noncovalently bound eGC components. 37 In the current study, we detected a wider variety of eGCderived components because of the higher flow rate used and broad sampling of the entire vascular system. Our data, therefore, indicate that DISDIVO is well suited to proteomic profiling of the eGC in health and disease and could also be combined with other 'omics' technologies (glycomics, glycoproteomics, etc) to further distinguish pathological changes in the vascular mucosa. Future studies will be able to use DISDIVO to assess protein abundance, posttranslational modifications, lipid composition, and metabolite profiles in different vascular tissues (EC, SMC, and eGC), on diverse animal models at distinct stages of VED, to better define the molecular basis and progression of this pathogenic syndrome.
Limitations of the Current Methods and Areas Where Future Work Is Required
Current methods for in vivo study of vascular biology and VED in animal models include evaluation of vessel resistance, brachial artery flow, skin microvessels, pulse wave, to cite a few. 62 Furthermore, molecular alterations in targeted vascular beds can be assessed by microscopy and classic biochemistry methods. 63 However, none of these existing methods provide accurate information on specific molecular alterations that occur systemically during the pathogenesis and progression of VED. DISDIVO coupled to systems biology, as demonstrated in this study and given its discovery-driven nature, allows in vivo systemic characterization of vascular biology and VED pathogenesis. Although differential characterization of vascular layer proteomes in DISDIVO can be achieved by the dose-dependent relationship that specific proteomes establish with the concentration of the decellularizing agent used as indicated in this work, an intrinsic overlap of proteomes between all these vascular categories is still observed. Therefore, following with the analysis of DISDIVO data, further targeted experiments (eg, confocal microscopy and colocalization studies, complementary in vitro and ex-vivo approaches, etc) may be required to further investigate the nature and implications of the initial DISDIVO findings in the animal models of interest.
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